186018-45-1

Basic information

• Product Name: metreleptin
• Synonyms: metreleptin;Metreleptin impurity A
• CAS NO: 186018-45-1
• Molecular Weight: 0
• Mol File: 186018-45-1.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: metreleptin(CAS DataBase Reference)
• NIST Chemistry Reference: metreleptin(186018-45-1)
• EPA Substance Registry System: metreleptin(186018-45-1)

Safety Data

• Hazardous Substances Data: 186018-45-1(Hazardous Substances Data)

Usage

Description

Metreleptin, also known by its brand name Myalept, is a recombinant N-methionyl analog of the leptin protein. It was developed to treat lipodystrophy, a rare metabolic disorder characterized by the absence or impaired function of adipose tissue. Metreleptin was approved by the Japanese Ministry of Health, Labor and Welfare in March 2013 and by the US FDA in February 2014 for the treatment of generalized lipodystrophy. Leptin, the natural protein that metreleptin is based on, plays a crucial role in regulating energy balance, body weight, and metabolism.

Uses

Used in Lipodystrophy Treatment:
Metreleptin is used as a metabolic homeostasis regulator for the treatment of lipodystrophy. It helps in managing the symptoms and complications associated with the disorder, such as ectopic lipid deposition in organs, hepatomegaly, and severe insulin resistance.
Used in Obesity Research:
Although metreleptin is primarily approved for the treatment of lipodystrophy, its underlying mechanism of action makes it a subject of interest in obesity research. As a leptin analog, metreleptin has the potential to be explored for its effects on energy balance, body weight, and metabolism in the context of obesity treatment.
Used in Pharmaceutical Industry:
Metreleptin, under the brand name Myalept, is used in the pharmaceutical industry for the development and marketing of drugs targeting metabolic disorders. Its approval for the treatment of lipodystrophy has paved the way for further research and development of leptin-based therapies for other metabolic conditions.

Originator

Amgen (United States)